戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e events (pemphigoid, adrenal insufficiency, liver disorder).
2 y liver disease (NAFLD) is a complex chronic liver disorder.
3 ng novel therapeutic targets to treat such a liver disorder.
4 r to Byler disease, an inherited cholestatic liver disorder.
5  or during an acute or decompensated chronic liver disorder.
6 d may represent targetable pathways to treat liver disorders.
7  mice, can lead to a spectrum of cholestatic liver disorders.
8  as patients receiving transplants for other liver disorders.
9 ntial target for therapeutic intervention in liver disorders.
10 ases are likely to become the most prevalent liver disorders.
11  such as fenofibrate, in various cholestatic liver disorders.
12 cts from control rats or patients with other liver disorders.
13 cteristics of the subjects and etiologies of liver disorders.
14 stinal diseases, including human cholestatic liver disorders.
15 is, autoimmune, metabolic or alcohol-related liver disorders.
16 abling symptom accompanying many cholestatic liver disorders.
17  development and adverse outcome of multiple liver disorders.
18 velopment of strategies to treat HBV-induced liver disorders.
19 nist that might hold utility in treatment of liver disorders.
20 le formation in the treatment of cholestatic liver disorders.
21  a frequent and debilitating complication of liver disorders.
22 lth in individuals with gastrointestinal and liver disorders.
23 lly in individuals with gastrointestinal and liver disorders.
24 ns of this frequent disease in patients with liver disorders.
25 function and diagnosis of various kidney and liver disorders.
26               Hepatomegaly is a sign of many liver disorders.
27 or preservation of organ function in certain liver disorders.
28              The conference focused on fatty liver disorders.
29 lls is a promising strategy to treat various liver disorders.
30 y liver diseases, the most prevalent chronic liver disorders.
31 ncluding jaundice, hepatitis, cirrhosis, and liver disorders.
32 nd MASH, suggesting its involvement in these liver disorders.
33 or predictive testing for selected monogenic liver disorders.
34 le formation in the treatment of cholestatic liver disorders.
35 s of pregnancy (ICP) is a pregnancy-specific liver disorder affecting 0.5-2% of pregnancies.
36 n formulae for the treatment of jaundice and liver disorders, against the cholestasis using the alpha
37 pregnancy (ICP) is the most common obstetric liver disorder and is associated with an increased risk
38 r disease (NAFLD) is the most common chronic liver disorder and is strongly associated with obesity a
39 jor limitation for the cell-based therapy of liver disorders and for ex vivo biological screens.
40 t of sex-specific therapeutic approaches for liver disorders and regenerative medicine.
41 ions are a characteristic feature of several liver disorders and share similarities with cytoplasmic
42                              WD is a chronic liver disorder, and individuals with the disease present
43                                 Many chronic liver disorders are characterized by dysregulated immune
44 plain the association of celiac disease with liver disorders are discussed.
45                                              Liver disorders are important adverse effects associated
46                               Many metabolic liver disorders are refractory to drug therapy and requi
47 ls using these approaches to treat metabolic liver disorders as well as the recently reported remarka
48 hylation defects and TNF expression in human liver disorders associated with elevated TNFalpha.
49 cribes an increasingly prevalent spectrum of liver disorders associated with obesity and metabolic sy
50 ncoding ATP11C are responsible for blood and liver disorders, but the disease mechanisms are not know
51 ediction models for newly diagnosed cases of liver disorders by using logistic regression and neural
52 ody fluids and tissues have been observed in liver disorders, cancers, and other diseases, displaying
53  be developed for persons with metabolic and liver disorders caused by a Western-style diet.
54 imary sclerosing cholangitis (PSC) is a rare liver disorder characterized by biliary ducts inflammati
55                             Cholestasis is a liver disorder characterized by impaired bile flow, redu
56 g cholangitis (PSC) is a chronic cholestatic liver disorder characterized by inflammation and fibrosi
57 alcoholic steatohepatitis (NASH) is a severe liver disorder characterized by triglyceride accumulatio
58 er disease (NAFLD) encompasses a spectrum of liver disorders characterized by abnormal hepatic fat ac
59 ciated steatohepatitis (MASH) are two common liver disorders characterized by abnormal lipid accumula
60  metabolic syndrome, neurological disorders, liver disorders, etc.
61 on of Diseases (ICD)-10 codes in identifying liver disorders for register based research is not well-
62                Clinical trials for blood and liver disorders, for which delivery of CRISPR is not lim
63 plicated in the pathogenesis of a variety of liver disorders; however, the underlying mechanism remai
64  32-year-old first cousin had a self-limited liver disorder in childhood that resolved at age 9 years
65 r disease (NAFLD) is the most common chronic liver disorder in industrialized countries.
66 tty liver disease (NAFLD) is the most common liver disorder in the United States; however, few data a
67 of posttransplantation diabetes mellitus and liver disorders in HNF1B patients, these findings advoca
68         It can also be identified in various liver disorders including nonalcoholic fatty liver disea
69 bodies (MDBs), are characteristic of several liver disorders, including alcoholic and nonalcoholic st
70 tially along neovessels, in murine and human liver disorders, irrespective of etiology.
71 marrow failure, campylobacter infection, and liver disorder [n=1]; and pneumonia [n=1]) and none in t
72 ssion to non-alcoholic steatohepatitis, is a liver disorder of increasing clinical significance.
73 e be an ideal cell for in vivo therapies for liver disorders or for use in bioartificial liver device
74 eases such as acute liver failure, end-stage liver disorders, primary liver cancers, and certain gene
75                    Porto-sinusoidal vascular liver disorder (PSVD) is a rare disease that occasionall
76 ells and intestinal bacterial glycolipids in liver disorders remained unclear.
77 , celiac disease can coexist with autoimmune liver disorders such as autoimmune hepatitis, primary bi
78 nts and has a high probability of developing liver disorders such as fibrosis, cirrhosis, and cancer.
79 larly in patients with diabetes, obesity and liver disorders such as hepatitis C infection.
80 m contribute to the development of prevalent liver disorders such as hepatosteatosis.
81 bolic diseases linked to insulin resistance, liver disorders such as primary biliary cirrhosis or non
82 towards using ribozymes for the treatment of liver disorders such as viral hepatitis, adenovirus vect
83 ary cirrhosis (PBC) is a chronic cholestatic liver disorder that can progress to cirrhosis, shortenin
84     Nonalcoholic steatohepatitis (NASH) is a liver disorder that still demands improved treatment.
85 , still be of importance in multiple chronic liver disorders that display a ductular response such as
86 tment and were subsequently diagnosed with a liver disorder, the PPV for the diagnosis of jaundice wa
87 s an emerging global epidemic causing severe liver disorders, the molecular mechanisms of HCV pathoge
88                                          The liver disorders unique to pregnancy include hyperemesis
89  > 14 g/d, have cirrhosis or other non-NAFLD liver disorders, use steatogenic medication, or have dia
90 istered in two referral centers for vascular liver disorders were eligible for the study.
91        Keratin mutations predispose to human liver disorders, whereas their roles in intestinal disea
92 2 each in TP53, VHL, and BRCA1), 1 recessive liver disorder with hepatocellular carcinoma (TJP2), and
93 ng immunohistochemistry in 86 HCC arising in liver disorders with varied aetiology.
94  liver disease (MASLD) is the most prevalent liver disorder worldwide and can progress to steatohepat